Brief: Lansen Pharmaceutical enters into subscription agreement
24/03/2016 08:54
March 24 (Reuters) - Lansen Pharmaceutical Holdings Ltd 0503.HK : * Unit entered into the subscription agreement with Haotian * Says subscriber, Haotian (BVI) and CI Biotechnology also entered into the shareholders' agreement * Subscription consideration was determined based on the valuation of the 100% equity interest of haotian at US$30 million * Source text for Eikon ID:nHKS9g9g1s ((For more news, please click here 0503.HK )) ((Bengaluru Newsroom; +91 80 6749 1130))
Recent news on Lansen Pharmaceutical Holdings
See all newsBrief: Lansen Pharmaceutical Says Stock Exchange Approved Withdrawal Of Listing Of Shares From 9 AM, 19 Dec
Brief: Lansen Pharmaceutical Updates Withdrawal Of Listing Of Shares On Stock Exchange
Brief: Lansen Pharmaceutical Says Trading In Shares Will Be Halted
Brief: Lansen Pharmaceutical Posts FY Revenue Of $65.6 Mln VS $54.2 Mln
Brief: Lansen Pharmaceutical Sees Net Profit Attributable Of Approximately $8.1 Million For Year